10:25:21 EDT Mon 15 Jul 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:SMMT - SUMMIT THERAPEUTICS INC - https://www.summitplc.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SMMT - Q0.48.59·8.610.18.60+0.050.6186.41,5308708.47  8.64  8.3911.25  1.5210:07:58Jul 0315 min RT 2¢

Recent Trades - Last 10 of 870
Time ETExPriceChangeVolume
10:08:06Q8.600.05194
10:08:06Q8.600.05100
10:08:06Q8.600.05100
10:07:58Q8.600.051
10:07:55Q8.600.05100
10:07:55Q8.600.05100
10:07:53Q8.6050.055100
10:07:52Q8.600.0572
10:07:51Q8.600.05107
10:07:51Q8.600.05100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-07-03 16:15U:SMMTNews ReleaseSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-06-27 16:15U:SMMTNews ReleaseSummit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors
2024-06-03 05:30U:SMMTNews ReleaseSummit Raises $200 Million; Also Expands License Territories for Ivonescimab
2024-06-01 08:00U:SMMTNews ReleaseIvonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
2024-05-31 19:00U:SMMTNews ReleaseIvonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
2024-05-30 18:00U:SMMTNews ReleaseSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-30 14:29U:SMMTNews ReleaseIvonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
2024-05-01 07:00U:SMMTNews ReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
2024-04-24 16:30U:SMMTNews ReleaseSummit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
2024-04-11 16:30U:SMMTNews ReleaseSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
2024-04-10 07:00U:SMMTNews ReleaseSummit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
2024-03-22 07:00U:SMMTNews ReleasePromising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
2024-03-14 07:00U:SMMTNews ReleaseIntracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
2024-03-05 07:00U:SMMTNews ReleaseSummit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
2024-02-20 07:00U:SMMTNews ReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
2024-02-14 07:00U:SMMTNews ReleaseSummit Therapeutics to Host Fourth Quarter & Full Year 2023
2024-02-07 07:00U:SMMTNews ReleaseSummit Therapeutics to Present at Oppenheimer ¢ € ™s 34th Annual Healthcare Life Sciences Conference
2024-01-08 09:00U:SMMTNews ReleaseSummit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-03 07:30U:SMMTNews ReleaseSummit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-07 07:00U:SMMTNews ReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023